OpenAlex
PricingAboutJobs
Log inGet started
Work

Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA

HTML

Year: 2022
Type: article
Source: Clinical Drug Investigation
DOI: 10.1007/s40261-022-01160-8
Authors: Tadesse M. Abegaz, Vakaramoko Diaby, Fatimah Sherbeny, Askal Ayalew Ali
Institution: Florida Agricultural and Mechanical University
Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life
Subfield: Economics and Econometrics
Field: Economics, Econometrics and Finance
Domain: Social Sciences
Keywords: dapagliflozin, diabetic nephropathy, cost-effectiveness, SGLT2 inhibitors, ACE inhibitors, quality-adjusted life years, Medicare and Medicaid, adverse drug reactions, treatment costs
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W4281552441
FWCI: 2.202
Cites: 68
Cited by: 17
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms
Security